Loading
Korro Bio, Inc. Stock: price and insider trades · United States
US·Mcap US$130.8M
1 insider bought €68k of shares over the last 90 days, the latest filed 13 Aug 2026.
Korro Bio, Inc.: what insiders have been doing
This page follows insider dealings at Korro Bio, Inc. as filed with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 73 filings came from 16 insiders.
The record shows 4 purchases on the open market worth €2.1M, made by 2 insiders, against 30 sales worth €2.7M by 5 insiders. The amount is not disclosed for 11 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 1 major shareholder. One trade stands out by size: a purchase of €2.0M from Yang Rick, disclosed on 12 March 2026.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 13 August 2026, 65 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 73 filings, this issuer sits above that mark. Since 2021, the database holds 6 purchases and 82 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 6.4 m USD and net income at -117.3 m USD.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
177
Thresholds
n/a
Buy Volume
€3M
6 ops. · all time
Sell Volume
€3M
82 ops. · all time
Who traded when
BuySaleJean Francois Formela24 sales
Lynx1 Capital Management LP3 buys
Aiyar Ram2 sales
Dolan Oliver2 sales
Agarwal Vineet1 sale
Cerio Jeffrey1 sale
+2 other insiders
Since the insiders bought
- -36.1%Entry US$13.28 · Close 16 Oct 2026 US$8.49
- -17.7%Entry US$12.80 · Close at T+90 US$10.53
- -72.3%Entry US$62.99 · Close at T+365 US$17.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Korro Bio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$20.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.88
Analyst consensus
10 analystsStrong buy
US$10.00Target US$20.20(+127%)US$30.00
Income statement
RevenueUS$6.4M
EBITDA-US$83.1M-1299% margin
Net income-US$117.3M-1834.5% margin
Valuation
PER (forward)-2.0x
P/Book1.3x
Beta2.36
Balance sheet & cash
Market capUS$130.8M
Total debtUS$43.5M
Free Cash Flow-US$79.1M
Debt / Equity41%
Profitability & ownership
ROE-97.7%
ROA-28.0%
% insiders0.9%
% institutions105.2%
Last declaration on 15 September 2026
Declarations177 total
1,750 shares@ US$13.990.017% mcap0.6% of flowCommon StockSEC:0001030575-26-000014:1
6,602 shares@ US$14.120.065% mcap2.4% of flowCommon StockSEC:0001030575-26-000014:3
8,450 shares@ US$13.990.082% mcap3.1% of flowCommon StockSEC:0001030575-26-000014:0
31,888 shares@ US$14.120.31% mcap11.8% of flowCommon StockSEC:0001030575-26-000014:2
31,888 shares@ US$13.810.31% mcap10.0% of flowCommon StockSEC144:0001628280-26-061898
6,602 shares@ US$13.810.064% mcap4.6% of flowCommon StockSEC144:0001628280-26-061897
8,450 shares@ US$13.060.077% mcap2.5% of flowCommon StockSEC144:0001628280-26-061593
1,750 shares@ US$13.060.016% mcap1.1% of flowCommon StockSEC144:0001628280-26-061592
5 shares@ US$13.7160.0000% mcap0.0% of flowCommonSEC144:0001959173-26-006900
7,347 shares@ US$13.51380.069% mcap42.2% of flowCommon StockSEC:0001193125-26-387852:0
6 shares@ US$13.60330.0001% mcap0.0% of flowCommonSEC144:0001959173-26-006837
7,347 shares@ US$13.51370.069% mcap42.2% of flowCommonSEC144:0001959173-26-006800
249 shares@ US$13.960.0024% mcap0.1% of flowCommon StockSEC:0001030575-26-000012:0
51 shares@ US$13.960.0005% mcap0.0% of flowCommon StockSEC:0001030575-26-000012:1
51 shares@ US$13.730.0005% mcap0.0% of flowCommon StockSEC144:0001628280-26-059121
249 shares@ US$13.730.0024% mcap0.1% of flowCommon StockSEC144:0001628280-26-059122
23,584 shares@ US$14.000.23% mcap8.7% of flowCommon StockSEC:0001030575-26-000010:0
4,884 shares@ US$14.000.048% mcap1.8% of flowCommon StockSEC:0001030575-26-000010:1
23,584 shares@ US$13.220.22% mcap7.1% of flowCommon StockSEC144:0001628280-26-058030
4,884 shares@ US$13.220.045% mcap3.2% of flowCommon StockSEC144:0001628280-26-058029
1,775 shares@ US$13.960.017% mcap0.7% of flowCommon StockSEC:0001030575-26-000008:0
368 shares@ US$13.960.0036% mcap0.1% of flowCommon StockSEC:0001030575-26-000008:1
5,222 shares@ US$11.39980.042% mcap70.6% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:0
Canonical exit: 4 Nov 2026 (T+90)
1,462 shares@ US$13.18690.013% mcap22.9% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:1
Canonical exit: 8 Nov 2026 (T+90)
1,775 shares@ US$13.490.017% mcap0.5% of flowCommon StockSEC144:0001628280-26-055858
25 of 177 declarations
About Korro Bio, Inc.
Korro Bio, Inc. is a biopharmaceutical company focused on developing therapies based on RNA editing. It is listed on NASDAQ under the symbol XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
